RedDress Overview
RedDress is the developer of ActiGraft, an FDA-cleared regenerative wound care solution based on the companys proprietary patented technology for reproducing the bodys natural ability to heal wounds. ActiGraft enables healthcare providers to produce, in real-time, in vitro blood clots from a patients whole blood. Once applied, the blood clots serve as a protective covering, biologic scaffold, and wound microenvironment to help promote the bodys natural wound-healing processes.
Cumulative Funding Raised Over Time ($)
$5.0MJan 2020
$5.0MJul 2024
$16.5MMay 2020
$42.5MMay 2023
Latest News
growth-positive
"זה החלום של כל חברה רפואית": מדיקר תממן את הטיפול של רדדרס הישראלית
Israeli biotech company RedDress has received a Reimbursement Code from Medicare, the largest government insurance company in the United States, for its treatment of chronic wounds. This code allows doctors to receive payment from the insurance company for using the companys chronic wound treatment kit on their patients. The code is considered a significant barrier for companies in the medical field, as efforts are required to obtain it and it is difficult to achieve significant sales in the American market without it. Medicare will reimburse doctors $1,726 for each kit, up to a maximum of 20 kits per patient.
CustomersPartners
growth-positive
RedDress Launches ActiGraft PRO with G-Code Reimbursement Status for the US Wound Care Market
RedDress has announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage. ActiGraft PRO is a whole-blood wound care solution that eliminates the need for a centrifuge or a needle for blood transfer. The product is expected to significantly lower the cost of treatment and impact outcomes in patients where amputation is recommended. The company worked with the Centers for Medicare Services to amend the code of the National Coverage Determination for Blood-Derived Products for Chronic Non-Healing Wounds to include ActiGraft PROs procedure.
CustomersExpand
growth-positive
RedDress Raises $26 Million to Give Patients the Power to Heal Chronic Wounds Using Their Own Blood
RedDress, a company specializing in personalized and autologous wound management solutions, has raised a $26 million Series D round of funding. The investment will support the companys product adoption, global partnerships, and expansion of its blood-based technology for treating various conditions. RedDress has developed a proprietary blood-based technology called ActiGraft, which uses patients own blood to create an in-vitro blood clot that jump-starts the wound healing process. The company aims to provide a more cost-effective and efficient solution for chronic wounds, particularly diabetic ulcers. Since receiving FDA clearance and a CE Mark in 2020, ActiGraft has been used by over 6,000 patients worldwide. RedDress is based in Israel with a subsidiary in the United States.
Investment
growth-positive
RedDress Announces Positive Results Specifying Use on Complex Wounds
RedDress, a medical device company based in the U.S. and Israel, has announced that new data supports the effectiveness of their wound care product, ActiGraft+, on complex wounds. The data was published in a consensus paper, which included recommendations from a panel of 9 clinicians from the U.S. and Germany. The panel concluded that ActiGraft+ is a viable treatment option for complex wounds as it assists in autolytic debridement, achieves complete wound bed coverage, maintains a moist wound healing environment, and provides structural support necessary for wound healing.
Customers
growth-positive
RedDress Receives Vizient Innovative Technology Contract for ActiGraft® systems
RedDress, a global medical device company, has received a contract from Vizient, Inc., a leading healthcare performance improvement company. The contract signifies that RedDresss wound care products have unique qualities that can bring improvement to the healthcare industry. The agreement gives increased access to RedDresss ActiGraft products to Vizients member base, which includes academic medical centers, community hospitals, and non-acute healthcare providers. The ActiGraft system is an FDA-cleared wound care solution that enables healthcare providers to produce an in vitro blood clot from a patients whole blood. The contract is a growth-positive development for RedDress.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $42.5M |
| Last funding | Undisclosed |
| Stage | D |
| Rounds | 4 |
| Investors | 6 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | reddressmedical.com/ |
| Careers | Careers page |
Locations
Shkedim Street 11, Pardes Hanna-Karkur, Israel
Ponte Vedra Beach, FL, USA
Photos & Videos
1 item(s)
RedDress Business
Business models
B2B2C, B2B, B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
BiologicalsCellsTags (7)
pain-reliefhealthcare-providersdiabeteschronic-painmedical-devicesregenerative-medicinemedical-technologiesUse Cases
ActiGraft+ Procedure VideoGeographic Markets
IsraelUnited StatesRedDress Financials
$42.5M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
D
Funding stage
4
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$5.0MJan 2020
$5.0MJul 2024
$16.5MMay 2020
$42.5MMay 2023
Private Equity Funding
Undisclosed Round
Jul 2024
Undisclosed
Katao Venture Partners (Lead)
D Round
May 2023
$26M
Athoss, HCS Capital , Alpha LTI
Undisclosed Round
May 2020
$11.5M
Undisclosed Investor(s)
Seed
Jan 2020
$5M
Boston Harbor Angels (Lead)
RedDress Lifecycle
Cumulative Funding Raised Over Time
$5.0MJan 2020
$5.0MJul 2024
$16.5MMay 2020
$42.5MMay 2023
All Events
Undisclosed Round
Jul 2024
Undisclosed
Katao Venture Partners (Lead)
D Round
May 2023
$26M
Athoss, HCS Capital , Alpha LTI
Undisclosed Round
May 2020
$11.5M
Undisclosed Investor(s)
Seed
Jan 2020
$5M
Boston Harbor Angels (Lead)
RedDress News
13 articles
growth-positive
"זה החלום של כל חברה רפואית": מדיקר תממן את הטיפול של רדדרס הישראלית
Israeli biotech company RedDress has received a Reimbursement Code from Medicare, the largest government insurance company in the United States, for its treatment of chronic wounds. This code allows doctors to receive payment from the insurance company for using the companys chronic wound treatment kit on their patients. The code is considered a significant barrier for companies in the medical field, as efforts are required to obtain it and it is difficult to achieve significant sales in the American market without it. Medicare will reimburse doctors $1,726 for each kit, up to a maximum of 20 kits per patient.
CustomersPartners
growth-positive
RedDress Launches ActiGraft PRO with G-Code Reimbursement Status for the US Wound Care Market
RedDress has announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage. ActiGraft PRO is a whole-blood wound care solution that eliminates the need for a centrifuge or a needle for blood transfer. The product is expected to significantly lower the cost of treatment and impact outcomes in patients where amputation is recommended. The company worked with the Centers for Medicare Services to amend the code of the National Coverage Determination for Blood-Derived Products for Chronic Non-Healing Wounds to include ActiGraft PROs procedure.
CustomersExpand
growth-positive
RedDress Raises $26 Million to Give Patients the Power to Heal Chronic Wounds Using Their Own Blood
RedDress, a company specializing in personalized and autologous wound management solutions, has raised a $26 million Series D round of funding. The investment will support the companys product adoption, global partnerships, and expansion of its blood-based technology for treating various conditions. RedDress has developed a proprietary blood-based technology called ActiGraft, which uses patients own blood to create an in-vitro blood clot that jump-starts the wound healing process. The company aims to provide a more cost-effective and efficient solution for chronic wounds, particularly diabetic ulcers. Since receiving FDA clearance and a CE Mark in 2020, ActiGraft has been used by over 6,000 patients worldwide. RedDress is based in Israel with a subsidiary in the United States.
Investment
growth-positive
RedDress Announces Positive Results Specifying Use on Complex Wounds
RedDress, a medical device company based in the U.S. and Israel, has announced that new data supports the effectiveness of their wound care product, ActiGraft+, on complex wounds. The data was published in a consensus paper, which included recommendations from a panel of 9 clinicians from the U.S. and Germany. The panel concluded that ActiGraft+ is a viable treatment option for complex wounds as it assists in autolytic debridement, achieves complete wound bed coverage, maintains a moist wound healing environment, and provides structural support necessary for wound healing.
Customers
growth-positive
RedDress Receives Vizient Innovative Technology Contract for ActiGraft® systems
RedDress, a global medical device company, has received a contract from Vizient, Inc., a leading healthcare performance improvement company. The contract signifies that RedDresss wound care products have unique qualities that can bring improvement to the healthcare industry. The agreement gives increased access to RedDresss ActiGraft products to Vizients member base, which includes academic medical centers, community hospitals, and non-acute healthcare providers. The ActiGraft system is an FDA-cleared wound care solution that enables healthcare providers to produce an in vitro blood clot from a patients whole blood. The contract is a growth-positive development for RedDress.
Partners
growth-positive
RedDress Secures Agreement with Premier, Inc., a Leading Group Purchasing Organization
RedDress, a wound care company, has been awarded a group purchasing agreement with Premier Inc. This partnership allows Premier members access to RedDress wound care product, ActiGraft® system. ActiGraft is the first wound care product that enables healthcare providers to produce an in vitro blood clot from a patients own blood. The agreement is expected to improve patient outcomes and aligns with Premiers mission to transform healthcare. RedDress is committed to developing effective treatments for chronic wounds and improving the health and lives of patients worldwide.
Partners
growth-positive
RedDress Earns a Strategic Partnership with MediGroup
RedDress has entered into a partnership with MediGroup, a group purchasing organization, to deliver its wound care solution, ActiGraft, to MediGroups members. ActiGraft aims to provide an affordable and effective wound solution for patients with chronic, non-healing wounds. The partnership allows RedDress to deliver ActiGraft to healthcare providers at an affordable cost. MediGroup, with over 250,000 healthcare employees, will benefit from RedDress advanced wound care products. ActiGraft is an FDA-cleared wound care solution that enables healthcare providers to produce an in vitro blood clot from a patients own blood, supporting the bodys natural wound healing response. RedDress is a privately held company based in Israel, with a U.S. subsidiary in Florida.
Partners
growth-positive
RedDress Announces Distribution Agreements in 12 European Countries
RedDress, a wound care company, has announced strategic distribution agreements in 12 European countries to distribute its wound care solution, ActiGraft. The agreements will support the companys global mission to improve the health and lives of patients with chronic wounds. ActiGraft is an innovative solution that enables healthcare providers to produce an in vitro blood clot from a patients own blood, which supports the natural wound healing response. The distribution agreements will accelerate RedDress growth globally and provide Europeans with an effective alternative treatment for chronic wounds. The company aims to expand access to ActiGraft in Austria, Cyprus, Czech Republic, Germany, Greece, Poland, Romania, Slovakia, Slovenia, Switzerland, Turkey, and Ukraine.
Customers
growth-positive
RedDress' ActiGraft® System Receives New FDA 510(k) Clearance
RedDress, a wound care company, has received FDA 510(k) clearance for its RD2 Ver.02 system, a continuation of its ActiGraft system. The ActiGraft Ver.02 System is used for the preparation of Whole Blood Clot (WBC) from a patients own blood to be applied topically to wounds. The FDA clearance allows RedDress to introduce the next generation of the ActiGraft system and shows their commitment to supporting healthcare providers and advancing wound treatment. The ActiGraft system has been rapidly adopted nationally and internationally since its launch in 2020. RedDress aims to improve the lives of patients with non-healing wounds. The company is privately held and has a subsidiary in the US.
Customers
growth-positive
How this Israeli serial inventor's bike accident gave birth to an innovative start-up
RedDress, an Israeli start-up, has developed a method for treating deep chronic wounds that dont respond to medical treatment. The company sells wound kits under the name ActiGraft, which prepare a blood clot outside the body. The kit includes syringes, test tubes for taking blood, clotting substances, a concave pan to create a blood clot, and additional equipment. The company received FDA approval last November and approval from the European CE and Israeli Health Ministry in December. RedDress recently completed a $11.5 million fundraising round.
InvestmentExpand
growth-positive
רדרס בנבחרת הסטארטאפים 2020 של TheMarker
RedDress, a medical technology company, has a unique patent for a biological product that aids in the healing of chronic wounds that do not respond to medical treatments. The company has raised $16.5 million in investment and plans to expand its workforce. The article discusses the challenges faced by the tourism industry and the impact on the high-tech job market.
InvestmentExpand
growth-positive
RedDress Announces Launch of ActiGraft, FDA-Cleared for the Treatment of Chronic and Acute Wound Types
RedDress has announced the U.S. launch of ActiGraft, a wound treatment that transforms a patients blood into an autologous whole blood clot tissue. ActiGraft recently received FDA clearance and is designed to promote the natural wound healing processes of the body. The treatment offers faster healing, reduced patient pain, and time-saving benefits for healthcare facilities. RedDress aims to address the unmet need for effective treatments for chronic wounds and improve the lives of patients. The company is privately held and has a U.S. subsidiary based in Florida.
Customers
growth-positive
RedDress Receives FDA 510(k) Clearance for RD1 System
RedDress Ltd has received FDA 510(k) clearance for its RD1 system, an innovative wound care product. The clearance allows RedDress to introduce the RD1 System to the U.S. market. The company aims to provide wound care technology that improves patient outcomes. RedDress is a private medical device company based in Israel, founded in 2009.
Customers
RedDress Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 33 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
RedDress Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 514264811 |
| Crunchbase | reddress |
| Creator | Maor Perlov |
| Creator email | maorperlov@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-01T00:00:00.000Z |
| Created | 2020-08-04T00:00:00.000Z |